Survodutide shows modest weight loss in phase 3 diabetes trial, trailing competitors
Boehringer Ingelheim's investigational dual GIP/GLP-1 agonist survodutide achieved up to 9.8% weight loss in the phase 3 SYNCHRONIZE-2 trial for adults with type 2 diabetes and obesity, meeting primary endpoints but falling short of competing drugs. The results raised tolerability concerns and led to a drop in partner Zealand Pharma's stock.
